MicroRNA‑193b regulates human ovarian cancer cell growth via targeting STMN1

Li,Haiyan; Xu,Yuping; Zhao,Danni

doi:10.3892/etm.2020.9033

MicroRNA‑193b regulates human ovarian cancer cell growth via targeting STMN1

Authors:
- Haiyan Li
- Yuping Xu
- Danni Zhao
View Affiliations

Affiliations: Department of Gynaecology, Shi Jia Zhuang The Third Hospital, Shijiazhuang, Hebei 050011, P.R. China
Published online on: July 23, 2020 https://doi.org/10.3892/etm.2020.9033
Pages: 3310-3315

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the eighth most common malignancy among women worldwide. Ovarian cancer exhibits no obvious symptoms in the early stage of tumorigenesis and currently, no effective methods for the early detection and treatment of ovarian cancer have been established. Therefore, the identification of novel targets is critical to the early diagnosis and clinical treatment of ovarian cancer. microRNAs (miRs) are small non‑coding RNAs, which serve an important biological role in a number of physiological processes and in oncogenesis. Previous studies have reported that miRNA‑193b is dysregulated in a variety of types of human cancer. However, the roles of miRNA‑193b in human ovarian cancer has not been determined. The present study investigated the roles of miRNA‑193b in human ovarian cancer cells. Reverse transcription‑quantitative PCR results indicated that the expression of miRNA‑193b in ovarian cancer cells was significantly down‑regulated compared with non‑malignant cells. Cell counting kit‑8 results indicated that the up‑regulation of miRNA‑193b inhibited ovarian cancer cell proliferation and induced ovarian cancer cell apoptosis. The present study also indicated that stathmin 1 (STMN1) was a direct target of miRNA‑193b, and the up‑regulation of miRNA‑193b significantly decreased the expression of STMN1 in ovarian cancer cells. In conclusion, the results demonstrated that miRNA‑193b serves as a tumor suppressor in human ovarian cancer by inhibiting cell proliferation and inducing cell apoptosis. Therefore, the assessment of miRNA‑193b may provide insight into a novel diagnostic biomarker and potential therapeutic target for patients with ovarian cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.PubMed/NCBI View Article : Google Scholar
3	Weidle UH, Dickopf S, Hintermair C, Kollmorgen G, Birzele F and Brinkmann U: The role of micro RNAs in breast cancer metastasis: Preclinical validation and potential therapeutic targets. Cancer Genomics Proteomics. 15:17–39. 2018.PubMed/NCBI View Article : Google Scholar
4	Jiang YW and Chen LA: microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (review). Mol Med Rep. 5:890–894. 2012.PubMed/NCBI View Article : Google Scholar
5	Kelly BD, Miller N, Healy NA, Walsh K and Kerin MJ: A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 111:3–4. 2013.PubMed/NCBI View Article : Google Scholar
6	Nair VS, Maeda LS and Ioannidis JP: Clinical outcome prediction by microRNAs in human cancer: A systematic review. J Natl Cancer Inst. 104:528–540. 2012.PubMed/NCBI View Article : Google Scholar
7	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009.PubMed/NCBI View Article : Google Scholar
8	Glud M, Rossing M, Hother C, Holst L, Hastrup N, Nielsen FC, Gniadecki R and Drzewiecki KT: Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res. 20:479–484. 2010.PubMed/NCBI View Article : Google Scholar
9	Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007.PubMed/NCBI View Article : Google Scholar
10	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.PubMed/NCBI View Article : Google Scholar
11	Yin W, Nie Y, Chen L, Wang Q, Liu S, He X and Wang W: Deregulation of microRNA-193b affects the proliferation of liver cancer via myeloid cell leukemia-1. Oncol Lett. 15:2781–2788. 2018.PubMed/NCBI View Article : Google Scholar
12	Wu H and Zhou C: Long non-coding RNA UCA1 promotes lung cancer cell proliferation and migration via microRNA-193a/HMGB1 axis. Biochem Biophys Res Commun. 496:738–745. 2018.PubMed/NCBI View Article : Google Scholar
13	Fang C, Dai CY, Mei Z, Jiang MJ, Gu DN, Huang Q and Tian L: microRNA-193a stimulates pancreatic cancer cell repopulation and metastasis through modulating TGF-β2/TGF-βRIII signalings. J Exp Clin Cancer Res. 37(25)2018.PubMed/NCBI View Article : Google Scholar
14	Chan CM, Lai KKY, Ng EKO, Kiang MN, Kwok TWH, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, et al: Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients. Oncol Lett. 15:3273–3280. 2018.PubMed/NCBI View Article : Google Scholar
15	Han D, Wang J and Cheng G: LncRNA NEAT1 enhances the radio-resistance of cervical cancer via miR-193b-3p/CCND1 axis. Oncotarget. 9:2395–2409. 2017.PubMed/NCBI View Article : Google Scholar
16	Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS and Osann K: Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 108:521–528. 2006.PubMed/NCBI View Article : Google Scholar
17	Fabbri M, Ivan M, Cimmino A, Negrini M and Calin GA: Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 7:1009–1019. 2007.PubMed/NCBI View Article : Google Scholar
18	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005.PubMed/NCBI View Article : Google Scholar
19	Brown JR and Sanseau P: A computational view of microRNAs and their targets. Drug Discov Today. 10:595–601. 2005.PubMed/NCBI View Article : Google Scholar
20	Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, et al: Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. 35:76–85. 2014.PubMed/NCBI View Article : Google Scholar
21	Zhou H, Wang K, Hu Z and Wen J: TGF-β1 alters microRNA profile in human gastric cancer cells. Chin J Cancer Res. 25:102–111. 2013.PubMed/NCBI View Article : Google Scholar
22	Cheung TH, Man KN, Yu MY, Yim SF, Siu NS, Lo KW, Doran G, Wong RR, Wang VW, Smith DI, et al: Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle. 11:2876–2884. 2012.PubMed/NCBI View Article : Google Scholar
23	Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL, et al: CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene. 32:2282–2291. 2013.PubMed/NCBI View Article : Google Scholar
24	Wu W, Lin Z, Zhuang Z and Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 18:50–55. 2009.PubMed/NCBI View Article : Google Scholar
25	Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, Oja H and Visakorpi T: miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer. 127:1363–1372. 2010.PubMed/NCBI View Article : Google Scholar
26	Chen J, Feilotter HE, Paré GC, Zhang X, Pemberton JG, Garady C, Lai D, Yang X and Tron VA: MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 176:2520–2529. 2010.PubMed/NCBI View Article : Google Scholar
27	Li H, Xu Y, Qiu W, Zhao D and Zhang Y: Tissue miR-193b as a novel biomarker for patients with ovarian cancer. Med Sci Monit. 21:3929–3934. 2015.PubMed/NCBI View Article : Google Scholar
28	Kueh HY and Mitchison TJ: Structural plasticity in actin and tubulin polymer dynamics. Science. 325:960–963. 2009.PubMed/NCBI View Article : Google Scholar
29	Rana S, Maples PB, Senzer N and Nemunaitis J: Stathmin 1: A novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 8:1461–1470. 2008.PubMed/NCBI View Article : Google Scholar
30	Rubin CI and Atweh GF: The role of stathmin in the regulation of the cell cycle. J Cell Biochem. 93:242–250. 2004.PubMed/NCBI View Article : Google Scholar
31	Belletti B and Baldassarre G: Stathmin: A protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 15:1249–1266. 2011.PubMed/NCBI View Article : Google Scholar
32	Mistry SJ and Atweh GF: Role of stathmin in the regulation of the mitotic spindle: Potential applications in cancer therapy. Mt Sinai J Med. 69:299–304. 2002.PubMed/NCBI
33	Ke B, Wu LL, Liu N, Zhang RP, Wang CL and Liang H: Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer. Tumour Biol. 34:3137–3145. 2013.PubMed/NCBI View Article : Google Scholar
34	Tamura K, Yoshie M, Miyajima E, Kano M and Tachikawa E: Stathmin regulates hypoxia-inducible factor-1α expression through the mammalian target of rapamycin pathway in ovarian clear cell adenocarcinoma. ISRN Pharmacol. 2013(279593)2013.PubMed/NCBI View Article : Google Scholar